FundRx

FundRx does not publicly disclose a named CIO or managing partner list. Based on public record, the firm operates through a network of physician venture partners who source and diligence deals, with final investment decisions made by a central partnership group in Nashville. Specific names and titles have not been confirmed through the firm's own communications.

FundRx sources deals through a network of practicing clinicians who act as scouts and venture partners. These physicians encounter early-stage healthcare companies through their own clinical practice — seeing products, devices, or software workflows before they reach pitch decks or accelerators. This embedded-sourcing model gives the firm access to companies that often have not formally fundraised.

FundRx is structured for direct pre-seed and seed equity investments, not as a fund-of-funds. There is no public record of the firm making LP commitments into other venture funds. Its model is to write first checks directly into operating companies, then syndicate with domain-expert angels and specialist healthcare funds on follow-on rounds.

The firm targets pre-seed and seed-stage companies. FundRx's thesis is to invest at the earliest institutional entry point — often before a startup has revenue, a full team, or regulatory clearance — and reserve capital for follow-on participation through later seed rounds. The firm does not publicly lead growth-stage or late-stage rounds.

FundRx has not published an explicit exclusion list. Based on its investment activity, the firm does not invest in non-healthcare sectors such as enterprise SaaS, fintech, or consumer internet. Within healthcare, there is no public indication that the firm avoids regulated medical devices or diagnostics, but payer-facing or pharma-services deals have not been prominently featured in its known portfolio.